Bank of New York Mellon
INDV icon

Bank of New York Mellon’s Indivior Pharmaceuticals INDV Stock Holding History

Bank of New York Mellon’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5M Buy
744,074
+61,297
+9% +$2.22M 0.01% 1368
2026
Q1 		$20.8M Sell
682,777
-17,495
-2% -$578K ﹤0.01% 1519
2025
Q4 		$25.1M Buy
700,272
+350,839
+100% +$10.7M ﹤0.01% 1406
2025
Q3 		$8.42M Buy
349,433
+38,797
+12% +$812K ﹤0.01% 2032
2025
Q2 		$4.58M Buy
+310,636
New +$3.62M ﹤0.01% 2312
2024
Q3 		– Sell
-11,672
Closed -$188K – 4134
2024
Q2 		$188K Buy
+11,672
New +$211K ﹤0.01% 3954

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Bank of New York Mellon's INDV Position: Q2 2026 in Review

Bank of New York Mellon increased its Indivior Pharmaceuticals (INDV) stake by 9% in Q2 2026, buying an estimated $2.22M and bringing the position to 744,074 shares worth $30.5M. The position accounts for 0.01% of the portfolio, ranked #1368.

Bank of New York Mellon first reported a position in INDV in Q2 2024 and has held it in 6 quarters since. 140 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Bank of New York Mellon held 744,074 shares of Indivior Pharmaceuticals worth $30.5M as of Q2 2026.
  • Bank of New York Mellon bought 61,297 Indivior Pharmaceuticals shares in Q2 2026, an estimated $2.22M.
  • Indivior Pharmaceuticals made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1368 holding.
  • Bank of New York Mellon first reported a position in Indivior Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • 140 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.